Please select the option that best describes you:
Topics:
Internal Medicine • Rheumatology • Osteoporosis • Nephrology • Endocrinology • End stage kidney disease • Bone and Calcium Disorders
Given the risk of hypocalcemia in dialysis dependent patients treated with denosumab, what is the best method of treatment for osteoporosis for these patients, and should we be transitioning to a different agent?
Answer from: at Academic Institution
Hypocalcemia can be prevented by providing adequate calcium, 1,200-1,500mg in divided doses daily, and adequate calcitriol to absorb it. Good results also occur when the patient has tertiary hyperparathyroidism with hypercalcemia.
Sign in or Register to read more
Answer from: at Community Practice
Calcium and calcitriol should be effective.